Claims for Patent: 5,914,265

Summary for Patent: 5,914,265

Title:	Keratin K1 expression vectors and methods of use
Abstract:	A keratin K1 vector for expression of a nucleic acid sequence in an epidermal cell. The vector includes a 5\' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a keratin K1 3\' flanking region which regulates expression of a nucleic acid sequence, predominantly in the epidermis, and a linker which connects the 5\' flanking region to a nucleic acid. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. That is, the linker is not the normal gene associated with the 5\' and 3\' regions.
Inventor(s):	Roop; Dennis R. (Houston, TX), Rothnagel; Joseph A. (Houston, TX), Greenhalgh; David A. (Houston, TX), Yuspa; Stuart H. (Bethesda, MD)
Assignee:	Baylor College of Medicine (Houston, TX) The United States of America as represented by the Department of Health (Washington, DC)
Application Number:	08/147,777
Patent Claims:	1. A vector for expression of a nucleic acid sequence in an epidermal cell, wherein said nucleic acid sequence is other than a mammalian K1 keratin gene, said vector comprising, in operable association: a 5' flanking region from a mammalian gene including necessary sequences for expression of said nucleic acid sequence; a 3' flanking region from a mammalian K1 keratin gene which regulates expression predominantly in an epidermal cell of said nucleic acid sequence with which it is associated; and a linker connecting said 5' flanking region to said nucleic acid sequence, said linker having a position for inserting said nucleic acid sequence, wherein said linker lacks the coding sequences of a gene with which it is naturally associated. 2. The vector of claim 1, wherein said 3' flanking region is 3' to said position for inserting said nucleic acid sequence. 3. The vector of claim 1, wherein said 3' flanking region is 5' to said linker. 4. The vector of claim 1, wherein said vector further comprises a nucleic acid sequence. 5. The vector of claim 1 or 4, wherein said 5' flanking region includes a promoter, 5' UTR, and a first intron and intron/exon boundary in appropriate relationship for expression of said nucleic acid sequence. 6. The vector of claim 1 or 4, wherein said 3' flanking region includes a 3' UTR and a 3' NCR containing a transcriptional termination region. 7. The vector of claim 1 or 4, wherein said 3' flanking region is from a human keratin K1 gene. 8. The vector of claim 1 or 4, wherein said 5' flanking region is from a keratin K1 gene. 9. The vector of claim 5, wherein said 5' flanking region is approximately 1.2 kb, said first intron and intron/exon boundary is 1.0 kb, and said 3' flanking region is approximately 3.9 kb of a keratin K1 gene. 10. The vector of claim 5, wherein said 5' flanking region is approximately 1.2 kb, said first intron and intron/exon boundary is 1.0 kb, and said 3' flanking region is approximately 4.3 kb of a keratin K1 gene. 11. The vector of claim 1 or 4, wherein said 5' flanking region comprises nucleotides 1 to 46 of Sequence ID No. 1; said 3' flanking region comprises nucleotides 6891 to 10747 of Sequence ID No. 1; and said linker comprising nucleotide 2351 to 2376 of Sequence ID No. 2. 12. The vector of claim 1 or 4, wherein said 5' flanking region comprises nucleotides 1 to 46 of Sequence ID No. 1; said 3' flanking region comprises nucleotides 7895 to 7921 of Sequence ID No. 1; and said linker comprising nucleotide 2351 to 2376 of Sequence ID No. 2. 13. The vector of claim 1 or 4, wherein said 5' flanking region comprises nucleotides 1 to 46 of Sequence ID No. 1; said 3' flanking region comprises nucleotides 7924 to 7948 of Sequence ID No. 1; and said linker comprising nucleotide 2351 to 2376 of Sequence ID No. 2. 14. The vector of claim 4, wherein said nucleic acid sequence comprises genetic material coding for a protein, or a polypeptide. 15. The vector of claim 14, wherein said genetic material codes for a hormone, a growth factor, an enzyme, a drug, a tumor suppressor, a receptor, an apolipoprotein, a clotting factor, an antigen, an oncogene or a transforming gene. 16. The vector of claim 15, wherein said oncogene is selected from the group consisting of ras, fos, myc, erb, src, sis or jun. 17. The vector of claim 14, wherein said genetic material of said nucleic acid sequence contains the E6 or E7 transforming sequence of human papilloma virus. 18. The vector of claim 14, wherein said genetic material of said nucleic acid sequence encodes for a protein or polypeptide selected from the group consisting of a TGF-.alpha. sequence, proinsulin, insulin, insulin-like growth factor I, insulin-like growth factor II, insulin growth factor binding protein, epidermal growth factor, dermal growth factor, an angiogenesis growth factor Type IV collagen, laminin, nidogen, Type VII collagen, TGF-.beta., acidic fibroblast growth factor, angiogenin, cytokine receptor, and IL-1, IL-6 and IL-8, a viral capsid protein. 19. The vector of claim 1 or 4, wherein said vector further comprises a modulator sequence associated with said 3' flanking region or said 5' flanking region. 20. The vector of claim 19, wherein said modulator sequence comprises sequences responsive to calcium, Vitamin D or its metabolite, Vitamin A or its metabolite, or progesterone. 21. An isolated or cultured mammalian epidermal cell transformed with a vector for expression of a nucleic acid sequence, wherein said nucleic acid sequence is other than a mammalian K1 keratin gene, said vector comprising, in operable association: a 5' flanking region from a mammalian gene including necessary sequences for expression of said nucleic acid sequence; a 3' flanking region from a mammalian K1 keratin gene which regulates expression predominantly in an epidermal cell of said nucleic acid sequence with which it is associated; and a linker connecting said 5' flanking region to said nucleic acid sequence, said linker having a position for inserting said nucleic acid sequence, wherein said linker lacks the coding sequences of a gene with which it is naturally associated. 22. The epidermal cell of claim 21, wherein said 5' flanking region includes a promoter, 5' UTR, and a first intron and intron/exon boundary in appropriate relationship for expression of said nucleic acid sequence. 23. The epidermal cell in claim 21, wherein said 5' flanking region is approximately 1.2 kb, said first intron and intron/exon boundary is 1.0 kb, and said 3' flanking region is approximately 3.9 kb of a keratin K1 gene. 24. The epidermal cell of claim 21, wherein said 5' flanking region is approximately 1.2 kb, said first intron and intron/exon boundary is 1.0 kb, and said 3' flanking region is approximately 4.3 kb of a keratin K1 gene. 25. The epidermal cell of claim 21, wherein said nucleic acid sequence comprises genetic material coding for a protein, or a polypeptide. 26. The epidermal cell of claim 25, wherein said genetic material codes for a hormone, a growth factor, an enzyme, a drug, a tumor suppressor, a receptor, an apolipoprotein, and an antigen. 27. The epidermal cell of claim 21, wherein said vector further comprises a modulator sequence in said 5' flanking region or said 3' flanking region. 28. The epidermal cell of claim 21, wherein said 3' flanking region includes a 3' UTR and a 3' NCR containing a transcriptional termination region. 29. The epidermal cell of claim 22, wherein said 5' flanking region comprises nucleotides 1 to 46 of Sequence ID No. 1; said 3' flanking region comprises nucleotides 6891 to 10747 of Sequence ID No. 1; and said linker comprising nucleotide 2351 to 2376 of Sequence ID No. 2. 30. The epidermal cell of claim 22, wherein said 5' flanking region comprises nucleotides 1 to 46 of Sequence ID No. 1; said 3' flanking region comprises nucleotides 7895 to 7921 of Sequence ID No. 1; and said linker comprising nucleotide 2351 to 2376 of Sequence ID No. 2. 31. The epidermal cell of claim 22, wherein said 5' flanking region comprises nucleotides 1 to 46 of Sequence ID No. 1; said 3' flanking region comprises nucleotides 7924 to 7948 of Sequence ID No. 1; and said linker comprising nucleotide 2351 to 2376 of Sequence ID No. 2. 32. The epidermal cell of claim 27, wherein said modulator sequence is responsive to calcium, vitamin D or its metabolite, vitamin A or its metabolite, or progesterone. 33. The epidermal cell of claim 27, wherein said 3' flanking region further includes an 18 KB EcoRV fragment. 34. The epidermal cell of claim 25, wherein said nucleic acid sequence encodes for proinsulin, insulin, insulin-like growth factor I, insulin-like growth factor II, insulin growth factor binding protein, epidermal growth factor, dermal growth factor, an angiogenesis growth factor Type IV collagen, laminin, nidogen, Type VII collagen, TGF-.beta., acidic fibroblast growth factor, angiogenin, cytokine receptor, and IL-1, IL-6 and IL-8, a viral capsid protein.

Details for Patent 5,914,265

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-06-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-06-22
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-06-22